AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04673266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: All patients will begin weekly (+/- 2 days) romiplostim at 3 mcg/kg subcutaneously. The romiplostim dose will be titrated, based on weekly CBC/platelet counts.
Study NCT02179762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence
Description: We will assess barriers to adhering to the exercise protocol by asking an open-ended question to solicit barriers. If the patient calls to cancel an exercise session, he will be called and probed for reasons
Study NCT01958593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with therapy administered in two blinded experimental sessions. Participants in this group in Stage 1 may take part in Stage 2.
Study NCT01958593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: Participants will receive MDMA-assisted therapy during two blinded experimental sessions. After unblinding, may receive a third session of open-label MDMA-assisted therapy.
Study NCT01958593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy before and after experimental sessions.
Study NCT01958593 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychotherapy
Description: Psychotherapy before and after experimental sessions.
Study NCT04089163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511
Description: Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal drug, flucytosine (5-fluorocytosine; 5-FC) to the anticancer drug 5-fluorouracil (5-FU) in cancer cells that have been infected by the Toca 511 vector.
Study NCT04089163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC (extended-release formulation of flucytosine)
Description: Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
Study NCT02103634 — intervention group
Intervention type: DEVICE
Intervention: NaF PET/MRI
Study NCT02103634 — intervention group
Intervention type: DEVICE
Intervention: NaF PET/CT
Description: NaF PET/CT images will be obtained through fusion software. Researchers will fuse the Non AC and AC NaF images with the low dose CT obtained in the FDG PET/CT study.
Study NCT02103634 — intervention group
Intervention type: DEVICE
Intervention: FDG PET/CT
Study NCT05371418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical (guided tissue regeneration)
Description: In group 1 (G1), ten teeth over erupted with angular bone loss were treated by guided tissue regeneration (GTR) followed by Orthodontic intrusion
Study NCT05371418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic intrusion followed by guided tissue regeneration GTR
Description: . In group 2 (G2), ten teeth over erupted with angular bone loss were treated by Orthodontic intrusion (OI) followed by guided tissue regeneration (GTR)
Study NCT02394431 — intervention group
Intervention type: OTHER
Intervention: Cardiac echography
Description: Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.
Study NCT02394431 — intervention group
Intervention type: OTHER
Intervention: Biological parameters
Description: Hemoglobin levels, red cells, hematocrit, iron, ferritin
Study NCT02394431 — intervention group
Intervention type: OTHER
Intervention: Clinical parameters
Description: Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness
Study NCT01096407 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Collection of urine samples
Study NCT01096407 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Completion of questionnaires
Study NCT01096407 — intervention group
Intervention type: PROCEDURE
Intervention: assessment of therapy complications
Description: An assessment will be completed.
Study NCT01412710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.
Study NCT02300818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Field Therapy
Description: Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.
Study NCT02300818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seawater eyedrops
Description: Eye-drops daily 1 time a day for 12 weeks
Study NCT01447316 — intervention group
Intervention type: OTHER
Intervention: Subject outcomes following bariatric surgery
Description: Subject outcomes (body composition, gait analysis, lower extremity joint pain and perceived quality of life) measured at per-op, 2, 4 weeks and 3 months.
Study NCT01457729 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivation by Telephone Call
Description: Telephone call not exceeding 10 minutes according to a protocol
Study NCT02428231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Participants will be dosed twice daily for 12 weeks.
Study NCT02428231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate
Description: Participants will be dosed twice daily for 12 weeks.
Study NCT03157310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Daily oral administration of 250 mg Gefitinib
Study NCT02179762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and body composition test
Description: Height will be measured to the nearest 0.1 cm and weight will be measured to the nearest 0.1 kg. Waist and hip circumference will be measured to the nearest 1/8 inch. Whole body dual-energy X-ray absorptiometry scans will be conducted at baseline and end of treatment to quantify total body fat.
Study NCT04527692 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: semi-structured interviews on the quality of life
Study NCT04012021 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 7T Magnetic Resonance Imaging
Description: * T1-weighted and T2-weighted sequences~* quantitative magnetic resonance imaging approach~* proton spectrum analyses
Study NCT02929771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung GearVR
Description: VR with head mounted display (HMD) and headphones. Treatment
Study NCT02929771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPad
Description: iPad with headphones. Control
Study NCT03458117 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec (T-VEC)
Description: a modified herpes simplex virus-1 (HSV-1) containing the gene coding for human granulocyte macrophage colony-stimulating factor (GM-CSF)
Study NCT02120118 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 2Gy/5fx/week for a subtotal of 40Gy/20fx/4 weeks, followed by reduced-field boost with 10Gy/2fx/2 weeks (5Gy once a week during 5th and 6th week), totalling 50Gy/22fx/6 weeks.
Study NCT02120118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: 42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times
Study NCT00464542 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole
Description: 500 mg, taken by mouth, two times a day, 7 days
Study NCT02818738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole Hydrochloride
Description: Dosage : 5, 10, 25 et 50 mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
Study NCT02818738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching verum
Study NCT03176160 — intervention group
Intervention type: OTHER
Intervention: Palliative regimen consisting of LITT
Description: Minimally invasive technique to necrotize intracranial lesions
Study NCT03936491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate is a central nervous system stimulant used for the therapy of attention deficit disorder and narcolepsy.
Study NCT03936491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD).\[6\] Use is only recommended in those who are at least six years old.\[6\] It is taken by mouth.\[6\]
Study NCT03961594 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: expansion volémique
Description: cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders.
Study NCT02873923 — intervention group
Intervention type: DRUG
Intervention: undefined
Description: Chemotherapy drug (meta-analyses of randomized trials)
Study NCT04092426 — intervention group
Intervention type: OTHER
Intervention: opthalmologic examination
Description: opthalmologic examination : Refraction Best corrected visual acuity Intraocular pressure Slit lamp examination
Study NCT04134663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vasoconstrictor and oxytocin treatment
Description: intransal administration of vasoconstrictor and oxytocin
Study NCT04134663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vasoconstrictor's placebo and oxytocin treatment
Description: intransal administration of vasoconstrictor's placebo and oxytocin
Study NCT04134663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vasoconstrictor and oxytocin's placebo treatment
Description: intransal administration of vasoconstrictor and oxytocin's placebo
Study NCT04449588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 Injection
Description: BDB-001 Injection+Conventional treatment
Study NCT04449588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.
Study NCT03801018 — intervention group
Intervention type: OTHER
Intervention: Questionnary and Interviews
Description: An internet platform dedicated to the anonymous survey will be set up by the communication department and the digital System Department of the promoter Public assistance hospitals in Marseille, the data Processing manager. It would deplore anonymous questionnaires accessible from a dedicated web page. People will therefore respond to a national survey on the basis of volunteering and anonymity.~Interviews, lasting one to two hours, will be fully transcribed and processed anonymously.~The interviews will seek to collect data on the modalities, conditions and effects of the circulation (or retention) of information on the use of donation, throughout the lives of individuals and families, in a cross-analysis of Viewpoints of parents and people born of donation.
Study NCT02946502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handheld dynamometry (handgrip strength)
Description: Patients will perform handgrip strength dynamometry through holding the device in their dominant hand with the maximum strength, with standardized arm and body positions, as well as incentives
Study NCT01444274 — intervention group
Intervention type: DEVICE
Intervention: Obalon Gastric Balloon(s)
Description: One or two balloons administered per patient
Study NCT00857493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE
Description: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Study NCT00857493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE
Description: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Study NCT04295044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high protein diet
Description: receive 1.8g protein/kg
Study NCT04295044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: normal protein diet
Description: receive 1g protein/kg
Study NCT01638637 — intervention group
Intervention type: DEVICE
Intervention: APTIMA Assays; PANTHER System
Description: APTIMA Assays; PANTHER System
Study NCT00561405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Learning Walking Program
Description: Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner. Sessions 45 minutes, 3x per week over 5 weeks for a total of 15 sessions
Study NCT00561405 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Weight Supported Treadmill Training
Description: Participants practice walking on a treadmill while supported with an overhead harness system. Up to 40% body weight support. Target Treadmill speed 2.0 mph. 1 or 2 Trainers (at least one Physical Therapist plus another Physical Therapist or Physiotherapy Assistant) will help guide participants leg, foot and trunk during treatment. Aim is to practice high numbers of repetition of the normal gait cycle on treadmill. Duration of sessions - 20 minutes of treadmill training within a 45 minute session ( 4 sets of 5 minutes of training with 5 minute rests). 3 sessions per week for 5 weeks. Total of 15 sessions.
Study NCT02777931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFC-1
Description: NFC-1 is supplied as size 2 hard gelatin capsules.
Study NCT02777931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study NCT03485131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct-current stimulation (tDCS)
Description: Stimulation sessions will be conducted twice a day on 5 consecutive weekdays. The twice daily sessions will be separated by at least 3 hours (one in the morning and the other one in the PM). The duration of treatment will be 4 weeks
Study NCT03485131 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo/sham stimulation: After 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse is delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
Study NCT03368547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study NCT03368547 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV
Study NCT03368547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT00103259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00103259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00103259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT03451331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting \~ 2-4 weeks after completing combination chemotherapy plus nivolumab)
Study NCT03451331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2
Study NCT03451331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 4.5 (based on the Calvert formula)
Study NCT03451331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2
Study NCT01680289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three adhesive coats
Description: After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime \& Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after a similar period a third layer will be applied over cavity walls. Again, after 20 seconds, the layers will be gently air-dried and photopolymerized by 10 seconds with a LED photoactivation unit.
Study NCT01680289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two adhesive coats
Description: After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime \& Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after 20 seconds, the layers will be gently air-dried by 5 seconds. The two layers will be photopolymerized by 10 seconds with a LED photoactivation unit.
Study NCT00501696 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 4.5 mg Naltrexone
Description: low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)
Study NCT00501696 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: 4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
Study NCT01092390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lovaza (fish oil)
Description: 4 grams per day
Study NCT01561586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Weekly cisplatin with RT
Description: Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)
Study NCT01561586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tri-weekly cisplatin with RT
Description: Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy~Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)
Study NCT01495169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloperidone (oral tablet)
Description: iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
Study NCT03958071 — intervention group
Intervention type: DRUG
Intervention: Nintedanib
Description: Nintedanib initiators
Study NCT03958071 — intervention group
Intervention type: DRUG
Intervention: Pirfenidone
Description: Pirfenidone initiators
Study NCT03958071 — intervention group
Intervention type: OTHER
Intervention: Untreated Cohort
Description: Untreated
Study NCT03334526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical training
Description: workout on treadmill requiring the muscles of the lower limbs mostly in concentric (ascent) or eccentric (downhill)
Study NCT03334526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mental training
Description: The task to imagine for the training group will be an abduction of the thumb
Study NCT03334526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: electrical stimulation of the muscles
Study NCT00574379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets
Study NCT00574379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets twice daily for 14 days
Study NCT00814619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given IV
Study NCT00814619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT00814619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Given orally
Study NCT00814619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo surgical resection